Who
Alfred Sandrock
President and CEO
Company insider
Files Form 4 as: President and CEO, Voyager Therapeutics; Head of Research & Development, Biogen; Director, Neurocrine Biosciences.
In numbers
- Trades disclosed
- 215
- Buys
- 0
- Sells
- 35
- Bought
- $0
- Sold
- $18.1M
- Companies
- 3
- Companies where not an officer
- 1
- First trade
- 16 Sep 2013
- Last trade
- 2 Apr 2026
- Last filed
- 3 Apr 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 2 Apr 2026filed 3 Apr 2026 | VYGR Voyager TherapeuticsBiotechnology | SEC FORM 4 Sold | $45K11,511 at $3.87 | filing |
| 2 Apr 2026filed 3 Apr 2026 | VYGR Voyager TherapeuticsBiotechnology | SEC FORM 4 Sold | $45K11,511 at $3.87 | filing |
| 24 Feb 2026filed 26 Feb 2026 | VYGR Voyager TherapeuticsBiotechnology | SEC FORM 4 Sold | $54K14,197 at $3.79 | filing |
| 24 Feb 2026filed 26 Feb 2026 | VYGR Voyager TherapeuticsBiotechnology | SEC FORM 4 Sold | $54K14,197 at $3.79 | filing |
| 18 Feb 2026filed 20 Feb 2026 | VYGR Voyager TherapeuticsBiotechnology | SEC FORM 4 Sold | $40K11,732 at $3.41 | filing |
| 18 Feb 2026filed 20 Feb 2026 | VYGR Voyager TherapeuticsBiotechnology | SEC FORM 4 Sold | $40K11,732 at $3.41 | filing |
| 10 Feb 2026filed 11 Feb 2026 | VYGR Voyager TherapeuticsBiotechnology | SEC FORM 4 Sold | $46K12,192 at $3.78 | filing |
| 10 Feb 2026filed 11 Feb 2026 | VYGR Voyager TherapeuticsBiotechnology | SEC FORM 4 Sold | $46K12,192 at $3.78 | filing |
| 6 Feb 2026filed 10 Feb 2026 | VYGR Voyager TherapeuticsBiotechnology | SEC FORM 4 Code A | —86,250 at $0.00 | filing |
| 6 Feb 2026filed 10 Feb 2026 | VYGR Voyager Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —402,500 at $0.00 | filing |
| 6 Feb 2026filed 10 Feb 2026 | VYGR Voyager Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —402,500 at $0.00 | filing |
| 6 Feb 2026filed 10 Feb 2026 | VYGR Voyager TherapeuticsBiotechnology | SEC FORM 4 Code A | —86,250 at $0.00 | filing |
| 2 Apr 2025filed 4 Apr 2025 | VYGR Voyager TherapeuticsBiotechnology | SEC FORM 4 Sold | $37K10,885 at $3.43 | filing |
| 21 Feb 2025filed 24 Feb 2025 | VYGR Voyager Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —290,000 at $0.00 | filing |
| 21 Feb 2025filed 24 Feb 2025 | VYGR Voyager TherapeuticsBiotechnology | SEC FORM 4 Code A | —145,000 at $0.00 | filing |
| 20 Feb 2025filed 24 Feb 2025 | VYGR Voyager TherapeuticsBiotechnology | SEC FORM 4 Sold | $50K11,702 at $4.24 | filing |
| 11 Feb 2025filed 12 Feb 2025 | VYGR Voyager TherapeuticsBiotechnology | SEC FORM 4 Sold | $74K16,644 at $4.45 | filing |
| 2 Apr 2024filed 3 Apr 2024 | VYGR Voyager TherapeuticsBiotechnology | SEC FORM 4 Sold | $119K12,115 at $9.86 | filing |
| 21 Feb 2024filed 22 Feb 2024 | VYGR Voyager TherapeuticsBiotechnology | SEC FORM 4 Sold | $97K13,033 at $7.46 | filing |
| 9 Feb 2024filed 16 Feb 2024 | VYGR Voyager Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —260,000 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.